Atlas Trials

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Clinical trial NCT02460276 · COMPLETED

Trial details

NCT number
NCT02460276
Sponsor
Lund University Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Mantle Cell Lymphoma
Start date
2015-04-01
Primary completion
2019-12-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.